Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.  

The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The round also included returning investors, the National Brain Tumor Society’s Brain Tumor Investment Fund and Cancer Research Horizons.  

Trogenix’s approach to cancer treatment is to combine the dual power of cancer cell killing and immune stimulation, delivered via a Trojan Horse approach that reawakens the immune system to provide long-term protection against tumour recurrence.  

Its lead programme in glioblastoma (GBM) is advancing towards clinical trials with the first patients expected to be dosed in Q1 2026.  

Ken Macnamara, Chief Executive Officer at Trogenix, added: “This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus platform. 

“We are honoured to have the continued support of our founding investors, 4BIO Capital and I would like to thank Dima and the team for their tireless work and enthusiasm. I also thank and welcome our existing and new investors, who share our mission to deliver breakthrough treatments and pursue cures for the thousands of patients and families facing devastating diagnoses each year.” 

Reece Armstrong, Editor, DDW